IGC Pharma, Inc.

IGC Pharma's Alzheimer's Agitation Drug Candidate Now Patented in the U.S., Canada, and Mexico as Phase 2 Readout Nears

Canada grants patent on IGC-AD1, an investigational oral therapy for agitation in Alzheimer's disease. Agitation is one of the hardest symptoms for…